Compound class:
Synthetic organic
Comment: SX682 is a selective and reversible antagonist (negative allosteric modulator) of the C-X-C motif chemokine receptors CXCR1 and CXCR2. It is orally bioavailable and is being investigated for potential anti-inflammatory and antineoplastic activities. It was developed by Syntrix Pharmaceuticals. The chemical structure presented here was obtained from the NIH's NCI drug Dictionary
|
|
No information available. |
Summary of Clinical Use ![]() |
A Phase 1 study of SX682 in combination with pembrolizumab has been registered with ClinicalTrials.gov; see NCT03161431. This trial will be carried out in patients with stage 3 and 4 metastatic melanoma. |